EVENTS

2019/03/14
Dravet 症候群ゼブラフィッシュモデルによる抗てんかん薬in vivoフェノミックスクリーニングシステム

2018/11/20
次世代ゼブラフィッシュ創薬とプレシジョンメディシン

2018/10/10
次世代ゼブラフィッシュ創薬と患者がん移植によるプレシジョンメディスン

2018/08/31
次世代ゼブラフィッシュ創薬の展開

2018/07/27
ゼブラフィッシュによる発生毒性試験とサリドマイド

》Dravet 症候群ゼブラフィッシュモデルによる抗てんかん薬in vivoフェノミックスクリーニングシステム

                     
2019/03/14

三重大学大学院医学系研究科システムズ薬理学岡村実奈さんが、第92回日本薬理学会年会で、報告予定です。
in vivo Phenomic Screening System for Antiepileptic Drugs using Dravet Syndrome Zebrafish Model
Epilepsy is a common chronic neurological disease affecting almost 1 million people in Japan and 50 million people worldwide. Despite availability of more than two dozen FDA-approved antiepileptic drugs, one-third of patients fail to receive adequate seizure control. Specifically, pediatric genetic epilepsies are often the most severe, debilitating and pharmaco-resistant forms of epilepsy.
The discovery of epilepsy associated genes suggests varied underlying pathologies and opens the door for development of precision medicine for each genetic epilepsy. Over 80% of patients diagnosed with Dravet syndrome carry a de novo mutation within the voltage-gated sodium channel gene SCN1A and these patients suffer with drug resistant and life-threatening seizures. Here we have developed zebrafish models for Dravet syndrome featuring inactivation of SCN1A with an emphasis on phenomics. we will also report recent drug screening efforts using our models with a focus on assay protocols and predictive pharmacological profiles. As the discovery and development phase rapidly moves from the lab-to-the-clinic for Dravet syndrome, it is hoped that this zebrafish-based drug discovery strategy offers a platform for how to approach any genetic epilepsy.

関連リンク

第92回日本薬理学会年会

三重大学メディカルゼブラフィッシュ研究センター